Skip to Content
Merck
CN

C5913

4-Chloromercuribenzoic acid

cysteine active site modifier

Synonym(s):

4-(Chloromercurio)benzoic acid, 4-(Hydroxymercuri)benzoic acid

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Linear Formula:
ClHgC6H4CO2H
CAS Number:
Molecular Weight:
357.16
UNSPSC Code:
12352202
NACRES:
NA.77
PubChem Substance ID:
EC Number:
200-442-6
Beilstein/REAXYS Number:
3662892
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

4-Chloromercuribenzoic acid, cysteine active site modifier

InChI

1S/C7H5O2.ClH.Hg/c8-7(9)6-4-2-1-3-5-6;;/h2-5H,(H,8,9);1H;/q;;+1/p-1

InChI key

YFZOUMNUDGGHIW-UHFFFAOYSA-M

SMILES string

OC(=O)c1ccc([Hg]Cl)cc1

description

cysteine active site modifier

assay

≥98.5% (HPLC)

form

powder

mp

287 °C (dec.) (lit.)

solubility

1 M NaOH: 20 mg/mL, clear, colorless

Looking for similar products? Visit Product Comparison Guide

Disclaimer

For U.S. Customers: Contains mercury; Do not place in trash - dispose according to local, state, or federal laws.

Application

Can be used to inhibit some enzymes that require unmodified cysteine residues (e.g., adenylyl cyclase).

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - STOT RE 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mamoon Rashid et al.
The Journal of pharmacology and experimental therapeutics, 335(3), 754-761 (2010-09-24)
We have discovered a non-AT(1), non-AT(2) angiotensin binding site in rodent and human brain membranes, which, based on its pharmacological/biochemical properties and tissue distribution, is different from angiotensin receptors and key proteases processing angiotensins. In this study, the novel angiotensin
Suresh Katragadda et al.
International journal of pharmaceutics, 320(1-2), 104-113 (2006-05-25)
The aim of this study is to identify the class of enzymes responsible for the hydrolysis of amino acid and dipeptide prodrugs of acyclovir (ACV) and to modulate transport and metabolism of amino acid and dipeptide prodrugs of acyclovir by
Margaret Yole et al.
Toxicology, 231(1), 40-57 (2007-01-11)
The effects of 1 min-4 h exposures to four Hg compounds (mercuric chloride [HgCl2], methyl mercuric chloride [CH3HgCl], p-chloromercuribenzoate [p-CMB] and thimerosal [TMS; ethylmercurithiosalicylate]) on cell death, microtubules, actin, CD3 receptor expression, protein tyrosine phosphorylation (PTyr-P) and intracellular calcium ([Ca2+]i)
Friederike Stumpff et al.
Pflugers Archiv : European journal of physiology, 457(5), 1003-1022 (2008-08-22)
The absorption of short-chain fatty acids (SCFA) from the rumen requires efficient mechanisms for both apical uptake and basolateral extrusion. Previous studies suggest that the rumen expresses a basolateral chloride conductance that might be permeable to SCFA. In order to
Dmitriy Minond et al.
Bioorganic & medicinal chemistry, 17(14), 5027-5037 (2009-06-26)
VIM-2 is an Ambler class B metallo-beta-lactamase (MBL) capable of hydrolyzing a broad-spectrum of beta-lactam antibiotics. Although the discovery and development of MBL inhibitors continue to be an area of active research, an array of potent, small molecule inhibitors is

Articles

Cancer research innovations address the complexity of the disease, providing advanced technologies for varied applications.

Biofiles reviews innovative technologies for cancer research, reflecting the complexity of the disease.

本期生物档案回顾了我们的一些最新和最具创新性的技术及其在癌症研究中的具体应用。在准备本期生物档案时,有人指出癌症极为复杂,要确定一个与其他主题完全无关的主题极为困难。。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service